Document is current
Any future updates will be listed below
-
Authors
Barry, Michael P.
Austin, Elizabeth J.
Bhatraju, Elenore P.
Glick, Sara N.
Stekler, Joanne D.
Tung, Elyse L.
Hansen, Ryan N.
Williams, Emily C.
Gojic, Alexander J.
Pickering, Eleanor I.
Tsui, Judith I.
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (1R34DA047660, 1R34DA047660, 1R34DA047660, 1R34DA047660, 1R34DA047660, 1R34DA047660, 1R34DA047660, 1R34DA047660, 1R34DA047660, 1R34DA047660, 1R34DA047660)
NIH/NIAID (P30AI027757, P30AI027757)
- License Information
-
More Information
Article History
Received: 25 March 2022
Accepted: 7 October 2022
First Online: 1 November 2022
Declarations
:
: All activities within the scope of this study were approved by the Institutional Review Board of the University of Washington. In accordance, all participants provided informed consent to participate in the study.
: Not applicable.
: JDS attended a Gilead Latinx Advisory Board Meeting in 2018. ELT attended advisory board meetings and speakers bureau for Gilead Sciences Inc. and is an advisory board meeting for Glaxso Kline Smith/ViiV. JIT is site-PI for a Patient-Centered Outcomes Research Institute (PCORI)-funded study (HERO Study) that used HCV medications donated by Gilead, also recipient of Small Business Innovation Research (SBIR) grants from NIH/NIDA (R44DA044053, R41DA053081; PI: Seiguer/Tsui) in partnership with a health technology company (emocha) to develop video-DOT app for buprenorphine and methadone.
